Is type 2 diabetes mellitus a predisposal cause for developing hepatocellular carcinoma?

Current Diabetes Reviews

Volumn 11, Issue 2, 2015, Pages 64-70

  Mukherjee, Biswajit ^a   Bhattacharya, Sanchari ^a   Chakraborty, Samrat ^a   Satapathy, Bhabani Sankar ^a   Dey, Niladri Shekhar ^a   Shaw, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Diabetes mellitus; Hepatocellular carcinoma; IL 6; Molecular mechanism; Risk factors; TNF

Indexed keywords

ANTIDIABETIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CANCER PROGNOSIS; DISEASE PREDISPOSITION; EXERCISE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; WEIGHT CONTROL; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE MANAGEMENT; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; CAUSALITY; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS;

EID: 84952661031     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811666150115110747     Document Type: Article

References (70)

1. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4: 369-80.
2. Blum HE. Hepatocellular Carcinoma: Therapy and prevention. World J gastroenterol 2005; 11:7391-00.
3. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363: 2339-50.
4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2009; 87: 4-14.
5. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 349: S62-9.
6. Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Comm Health 2009; 63: 332-36.
7. Behne T, Copur MS. Biomarkers for Hepatocellular Carcinoma. Int J Hepatol 2012; 7.
8. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S. Hepatocellular carcinoma: Consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 2010; 28: 3994-05.
9. Hossain CM, Satapathy BS, Mondal L, Chakraborty S, Mukherjee B. Effect of streptozotocin-induced hyperglycemia on the progression of hepatocarcinogenesis in rats. Am J Pharmacol Toxicol 2013; 8: 170-78.
10. Liu Y, Wu F. Global burden of aflatoxin induced hepatocellular carcinoma: A risk assessment. Environ Health Perspect 2010; 118: 818-24.
11. Das T, Patra F, Mukherjee B. Effect of antisense oligomer in controlling c-raf.1 over expression during diethylnitrosamine-induced hepatocarcinogenesis in rat. Cancer Chemother Pharmacol 2010; 65: 309-18.
12. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterol 2008; 134: 1752-1763.
13. Sun G, Kashyap SR. Cancer risk in type 2 Diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab 2011; Article ID 708183: 11.
14. Giovannucci E, Harlan DM, Archer MC. Diabetes and cancer: a consensus report, CA Cancer J Clinicians 2010; 60: 207-21.
15. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130: 1639-48.
16. Kamkar M, Ahmad R, Alsmadi O, Behbehani K. Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disorders 2014; 13: 57-63.
17. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochem Biophys Acta 2011; 1807: 664-78.
18. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer 2010; 10: 442.
19. Muntoni S. Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab 2011; 58: 25-36.
20. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011; 18: 139-43.
21. Pivonello C, Martino MC, Negri M, Cuomo G, Cariati F, Izzo F. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agents Cancer 2014; 9:27.
22. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signaling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004; 68: 1003-15.
23. Goodwin PJ. Insulin in the adjuvant breast cancer setting: A novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 2008; 26: 833-34.
24. Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab 2014; 3: 94-108.
25. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Medicine 2008; 14: 741-51.
26. Shoelson S, Lee J, Goldfine A. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-01.
27. Qatanani M, Lazar M. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Develop 2007; 21: 1443-55.
28. Ohnishi S, Ma N, Thanan R, et al. DNA damage in Inflammation-related carcinogenesis and cancer stem Cells. Oxidative medicine and cellular longevity 2013; Article ID 387014, 9.
29. Jiang N, Sun R, Sun Q. Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Design Develop Therap 2014; 8: 2295-02.
30. American Cancer Society, Liver Cancer Overview. 2014. http://www.cancer.org/acs/groups/cid/documents/webcontent/00305 8-pdf.pdf.
31. Mukherjee B, Hossain C, Mondal L, Paul P, Ghosh M. Obesity and insulin resistance: an abridged molecular correlation. Lipid Insights 2013; 6: 1-11.
32. Rolls BJ, Drewnowski A, Ledikwe JH. Changing the energy density of the diet as a strategy for weight management. J Am Diet Assoc. 2005; 105: S98-S103.
33. Blatt AD, Roe LS, Rolls BJ. Hidden vegetables: an effective strategy to reduce energy intake and increase vegetable intake in adults. Am J Clin Nutr 2011; 93: 756-63.
34. Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data. Int J Endocrinol 2013; 8.
35. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonal-coholic fatty liver disease. Seminars in Liver Disease 2008; 28: 360-69.
36. Hassan M, Steven A., Curley Li, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer (ACS) 2010; 116: 1938-46.
37. Donadon V, Massimiliano B, Michela G, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-11.
38. Siegel A, Zhu A. Metabolic Syndrome and hepatocellular carcinoma. Cancer (ACS) 2009; 115: 5651-61.
39. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-07.
40. El-Serag H, Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol 2007; 132: 2557-76.
41. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 2007; 117: 1175-83.
42. Nakagawa H, Maeda S, Yoshida H, et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009; 125: 2264-69.
43. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124: 2766-70.
44. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-08.
45. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-5.
46. Chen W, Li N, Chen T, et al. The lysosome-associated apoptosis-inducing protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway. The J Bio Chem 2005; 280: 40985-95.
47. Braunersreuther V, Viviani GL, Mach F, Montecucco F: Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenter 2012; 18: 727-35.
48. Jung KW, Ha E, Yu GI, et al. TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta 2009; 407: 16-9.
49. Theiss AL, Simmons JG, Jobin C, Lund PK.. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF Recptor 2. J Biol Chem. [Online] 2005. Available at: http://www.jbc.org/content/280/43/36099.long Accessed: 21/10/14
50. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
51. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumor promoter in inflammation-associated cancer. Nature 2004; 431: 461-66.
52. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006. 2006; re 13.
53. Bell BD, Leverrier S, Weist BM, Newton RH, Arechiga AF, Luhrs KA. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 16677-82.
54. Kant S, Swat W, Zhang S, et al. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 2011; 25: 2069-78.
55. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-21.
56. Jiang R, Xia Y, Li J, et al. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int J Cancer 2010; 126: 1263-74.
57. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-90.
58. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-09.
59. Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 1995; 15: 3463-69
60. Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 2006; 21: 15-21.
61. Goyal R, Faizy AF, Siddiqui SS, Singhai M. Evaluation of TNF-and IL-6 levels in obese and Non-obese diabetics: pre- and postinsulin effects. North Am J Med Sci 2012; 4: 180-84.
62. Dinh W, Füth R, Nickl W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009; 8: 58.
63. Warmkessel KE and co-workers. University of Maryland. Commonly Used Diabetes Drug May Help to Prevent Primary Liver Cancer. 2012.
64. Bhalla K, Hwang BJ, Dewi RE, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012; 5: 544-52.
65. Sumie S, Kawaguchi T, Kawaguchi A, et al. Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. Mol Clin Oncol 2014; 3: 115-20.
66. Armstrong MJ, Barton D, Gaunt P, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open 2013; 3: 13.
67. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-12.
68. Ortiz AP, Romero C, Disdier O, et al. Diabetes is associated with chronic liver disease and liver cancer in the adult population of Puerto Rico. PRHSJ. 2011; 30: 132-34.
69. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-83.
70. Picardi A, D’Avola D, Gentilucci UV, et al. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes. Metab Res Rev 2006; 22: 274-83.